Clinical Trial Update: Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) [Phase 2]

View source ↗

Summary

Phase 2 substudy MK-3475-01I/KEYMAKER-U01I evaluating investigational pembrolizumab-based therapy in previously treated stage IV squamous non-small cell lung ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Lung Neoplasm | Phase 2 | Status: RECRUITING